| umls-concept:C1435551 | skos:definition | NCI: An orally-active synthetic hydroxamic acid derivative with potential antineoplastic activity. MMI270 inhibits a broad spectrum of matrix metalloproteinases (MMPs) (specifically MMP-1, 2, 3, 9, and 13), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. This agent may also downregulate lymphangiogenesis, resulting in decreased lymphatic system-related metastasis. (NCI04) | lld:umls |
